New Horizons Diagnostic Corporation (NHD) develops and manufactures testing products for the detection of bacteria and toxins in human, environmental, surface, food, and water samples for government, municipal and corporate customers. It offers diverse medical products, such as products for testing cholera, gonorrhea, syphilis, and drug abuse screening products. The major product line for NHD is the development, marketing and sale of rapid antibody based diagnostic kits. World Health Organization (WHO) studies have shown that since 1996, infectious and parasitic diseases accounted for 43% of the 40 million deaths in developing countries. In the US alone, the death rate due to infectious diseases rose 58% from 1980 to 1992. The incidence of food-borne illness continues to rise. Emerging infectious diseases in animals with the potential to afflict human populations, such as BSE and avian influenza, continue to increase in number as well. As many as 81 million illnesses and 9,000 deaths occur each year in the US from food-borne microorganisms. In addition, pesticides in food give rise to an estimated 6,000 cancer cases annually in the US. The Environmental Protection Agency (EPA) estimated, in the early 1990s, that approximately 43% of the water systems serving 120 million people had EPA violations, and nearly one million people became ill due to contaminated water. The company also provides bio threat detection products, including diagnostic kits, collection kits, and environmental kits. The collaborative effort, if successful, will permit the identification and development of new and improved diagnostic kits for the targeted diseases. New Horizon Diagnostics matched DOE’s dollars through a Cooperative Research and Development Agreement (CRADA). That CRADA is the subject of this report. The proposal was ultimately funded and the CRADA between NHD and PNNL was established. PNNL managed the activities at the Russian State Diagnostic and Prevention Center for Human and Animal Diseases (DPC) and its collaborators (Ivanovsky Virology Institute, the All-Russian Institute for Animal Health (ARRIAH), and Gamaleya Institute) to support the efforts between NHD and DPC and it collaborators in developing commercially viable diagnostics and therapeutics.